Roche on the ropes with Avastin
An FDA panel has voted unanimously to withdraw approval for Roche's Avastin for use in the treatment of metastatic breast cancer because there is not enough data to support that the benefits outweigh the risks, despite an appeal from Roche. More... |
| |
EMA welcomes new directive on falsified medicines
The European Medicines Agency (EMA) has responded positively to a new directive published in the Official Journal of the European Union addressing concerns over increases in falsified medicines in the supply chain. More... |
| |
FDA Q11 draft guidance available for comment
The FDA has issued a draft guidance for comment entitled “Q11 Development and Manufacture of Drug Substances”, which describes approaches to developing process and drug substance understanding. More... |
| |
Sanofi targets tuberculosis treatments
Sanofi has entered into a research collaboration with the Weill Cornell Medical College in New York to develop new anti-infectives that aim to both shorten the course of treatment for tuberculosis and provide effective therapies against drug-susceptible and drug-resistant strains of the disease.
More... |
| |
Research spend on cancer doubles within a decade
Partners of the UK's National Cancer Research institute (NCRI) have nearly doubled their spend on cancer research in the last ten years.
More... |
| |
Join our community on LinkedIn
Want to discuss any of this week's news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More... |
| |
